Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure (AQUATIC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Korea Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Korea Otsuka Pharmaceutical Co., Ltd. Identifier:
First received: December 20, 2012
Last updated: November 29, 2016
Last verified: November 2016
The objective is to evaluate the efficacy and safety on the tolvaptan for increasing serum Na levels in patients with worsening heart failure and hyponatremia.

Condition Intervention Phase
Heart Failure With Hyponatremia
Drug: Tolvaptan
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Assessment of Clinical Outcome and Treatment Quality Under Adequate Use of Tolvaptan In Correction of Hyponatremia in Patients Hospitalized With Worsening Heart Failure and Hyponatremia

Resource links provided by NLM:

Further study details as provided by Korea Otsuka Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Average daily AUC of change from baseline in serum Na level to day 4 within the double-blind treatment period [ Time Frame: from baseline to day 4 ]

Secondary Outcome Measures:
  • Average amount of furosemide used during hospitalization. [ Time Frame: from day 1 to discharge date (up to subject condition day 2 ~ day 30) ]
  • Average amount of furosemide used during out-patient period. [ Time Frame: from baseline to day 30 and day 60 ]

Estimated Enrollment: 80
Study Start Date: December 2012
Estimated Study Completion Date: May 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tolvaptan
Tovaptan tablet 15mg, 30mg, 60mg, once a day, oral
Drug: Tolvaptan
Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
Other Name: Samsca
Placebo Comparator: placebo
placebo tablet 15mg, 30mg, 60mg, once a day, oral
Drug: Placebo
Start with 15mg to titrate upwards to 30mg to 60mg, once a daily

Detailed Description:
This is a phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel-group interventional study comparing tolvaptan (15 to 60 mg) to placebo in adult patients hospitalized (or admission to emergency room) due to worsening of heart failure and dilutional hyponatremia. All patients will be on standard therapy for heart failure.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients hospitalized due to heart failure with clinically significant hyponatremia (except hypovolemic) (defined as serum Na < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) prior to randomization.
  2. Male and female patients aged ≥ 20 years.
  3. New York Heart Association (NYHA) class III/Ⅳ
  4. Signs of extracellular volume expansion, defined as two or more of the following: JVD, peripheral edema, dyspnea or pulmonary congestion.
  5. B-type natriuretic peptide (BNP) ≥ 150 pg/mL or N terminal (NT)-proBNP ≥ 450 pg/mL.

Exclusion Criteria:

  1. Women who are pregnant, breast feeding, or of childbearing potential who are not using acceptable contraceptive methods
  2. Patients with hyponatremia in hypovolemic states, defined as the presence of clinical and historical evidence of extracellular fluid volume depletion
  3. Patients unable to sense or respond to thirst.
  4. Patients who are likely to require prolonged hospitalization for reasons other than chronic heart failure (CHF)
  5. Patients with recent prior treatment for hyponatremia
  6. Patients with severe hyponatremia symptoms requiring immediate intervention with hypertonic saline
  7. Patients with causes of neurological symptoms, which are attributable to psychological (psychoses), structural (dementia of the Alzheimer's type, post-infarct dementia) or other metabolic causes
  8. Patients with acute and transient hyponatremia associated with head trauma or severe neurological injury
  9. Patients with a history of hyponatremia known to be due to severe, untreated hypothyroidism/adrenal insufficiency.
  10. Patients with psychogenic polydipsia.
  11. Patients with systolic BP < 90 mmHg at screening.
  12. Patients with a history of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril), or tolvaptan.
  13. Patients with a history of drug or medication abuse within the 3 months prior to screening, or current alcohol abuse.
  14. Patients with uncontrolled diabetes mellitus
  15. Patients with a current urinary tract obstruction
  16. Anuric patients.
  17. Patients with a serum creatinine > 3.5 mg/dL at screening.
  18. Terminally ill patients or patients with a moribund condition who have little chance of short-term survival.
  19. Patients whose hyponatremia is the result of any medication that cannot safely be withdrawn, such as anti-convulsants and anti psychotics
  20. Patients receiving desmopressin within 2 days of screening.
  21. Patients who have participated in another investigational drug trial within the past 30 days.
  22. Any patient who, in the opinion of the investigator, would not be able to comply with the study drug administration or study procedures, or whose overall medical condition would prohibit their participation in the study.
  23. Patients treated and/or to be treated with strong cytochrome P450 (CYP) 3A inhibitors
  24. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose- galactose malabsorption.
  25. Patients with a AST or ALT > ULN 2.5 or total bilirubin > 2mg/dL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02352285

Contact: Ho Young Lee, BS +82-2-3287-9238

Korea, Republic of
Seoul National University Bundang Hospital Recruiting
Seoul, Korea, Republic of
Contact: Dong Ju Choi, Doctor    82-31-787-7007   
Sponsors and Collaborators
Korea Otsuka Pharmaceutical Co., Ltd.
Principal Investigator: Dongju Choi, MD Seoul National University Bundang Hospital
  More Information

Responsible Party: Korea Otsuka Pharmaceutical Co., Ltd. Identifier: NCT02352285     History of Changes
Obsolete Identifiers: NCT01865214
Other Study ID Numbers: 156-KOB-1201i
Study First Received: December 20, 2012
Last Updated: November 29, 2016

Additional relevant MeSH terms:
Water-Electrolyte Imbalance
Heart Failure
Heart Diseases
Cardiovascular Diseases
Metabolic Diseases
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs processed this record on April 21, 2017